Pall and Fresenius Kabi team up for prion reduction
This article was originally published in Clinica
East Hills, New York-based Pall has entered into a five-year commercialisation collaboration with Fresenius Kabi, of Bad Homburg, Germany, aimed at increasing European sales of prion reduction technology for blood transfusions.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.